Patients who are filing Ozempic vision loss lawsuits against Novo Nordisk had developed nonarteritic anterior ischemic optic neuropathy (NAION) while using Ozempic. These cases are product liability failure to warn lawsuits filed against the responsible drug company, Novo Nordisk, because the Ozempic drug label does not warn about NAION as a … [Read more...]
Vision Loss Linked to Rybelsus and Ozempic Use by Diabetes Patients
The relatively new drug safety issue of vision loss linked to Rybelsus and Ozempic was the subject of a recent medical study that had this stated Objective, or purpose: “To investigate the association between semaglutide use and the risk of NAION among patients with diabetes.” On March 27, 2025, the JAMA Ophthalmology medical journal published … [Read more...]
Semaglutide: Eyesight Loss From Drug Side Effect NAION
Semaglutide eyesight loss from the drug side effect NAION is being investigated as possible drug injury lawsuits to be filed on behalf of patients against Novo Nordisk, the responsible drug company for Ozempic, Wegovy, and Rybelsus. The active ingredient for each of those three Novo Nordisk drugs is semaglutide. There are a couple of recent … [Read more...]
Ozempic Vision Loss Due to Increased Risk of NAION
Here is the most recent development concerning Ozempic vision loss and blindness: The European Union’s drug regulator said it would assess two new Danish studies that link Novo Nordisk’s popular diabetes drug Ozempic to a rare eye disease. The studies published earlier this week had found Ozempic significantly increases the risk of type 2 … [Read more...]
Ozempic Side Effects Include Eye Problems With Possible Vision Loss
In July 2024 we learned from a recent medical study that Ozempic side effects include eye problems with possible vision loss. More specifically, nonarteritic anterior ischemic optic neuropathy (NAION) has been linked to semaglutide — the active ingredient in Ozempic as well as Wegovy and Rybelsus. As such, this finding about the new NAION Ozempic … [Read more...]